BF.7 coronavirus variant not worrisome for India: Scientist Rakesh Mishra

Allaying fears about BF.7 variant of coronavirus, a prominent scientist said it is a sub-variant of Omicron strain and that India need not worry too much about its severity on the population

coronavirus
Photo: Bloomberg
Press Trust of India Hyderabad
2 min read Last Updated : Dec 23 2022 | 10:27 AM IST

Allaying fears about BF.7 variant of coronavirus, a prominent scientist on Friday said it is a sub-variant of Omicron strain and that India need not worry too much about its severity on the population.

Speaking to PTI, Rakesh Mishra, Director, Tata Institute for Genetics and Society (TIGS), Bangalore, however cautioned that wearing face masks and avoiding unnecessary crowds is always advisable.

The former director of CSIR-Centre for Cellular and Molecular Biology further said China has been witnessing an unprecedented surge in COVID-19 cases as the neighbouring country has not passed through different waves of the infection that India had faced.

"This is a sub-variant of Omicron. Main features will be like Omicron except some small changes, there is no big difference. Most of us have gone through the Omicron wave. So, we don't have to worry about it. Essentially, it is the same virus," he said.

China is experiencing a surge in infections due to its "zero-Covid policy", under which authorities block apartment buildings or even cordon off a neighbourhood once a resident tests positive, causing great inconvenience to the people, the scientist said.

Mishra added that the Chinese population is not exposed to natural infection and they did not use the time to vaccinate the elderly people.

"So what is happening to those guys is, since they're not vaccinated, their symptoms are severe. Younger people still do not have any problem. But among older people who were not vaccinated, it is spreading very fast," he said about the situation in China.

According to him, most Indians have acquired hybrid immunity which means immunity developed through vaccines and also natural infection protecting them from different COVID-19 variants.

The scientist said the existing vaccines in India are good to prevent or thwart different Omicron variants also as several studies indicated that even in the big wave of Omicron earlier this year, India did not see many hospitalisations.

In view of the sudden spurt, in cases being witnessed in Japan, United States of America, Republic of Korea, Brazil and China, the Union Health Secretary Rajesh Bhushan on December 20, wrote a letter to all the state and Union territories.

He requested them to ensure that as far as possible samples of all positive cases, on a daily basis, are sent to designated INSACOG (Indian SARS-CoV-2 Genomic Consortium) genome sequencing laboratories that are mapped to the states and UTs.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus TestsVirusesScientists

First Published: Dec 23 2022 | 10:27 AM IST

Next Story